NAD+

NAD+ — nicotinamide adenine dinucleotide — is technically a coenzyme rather than a peptide, but it is commonly supplied and tracked in the same lyophilized-vial workflow as the peptides on this site. Vial sizes are typically much larger than peptide vials, often 100 mg or 500 mg.

Cadence varies widely between users. Weekly, twice-weekly, and intensive-loading protocols all appear in personal logs. The flexible cadence makes a structured dose log even more useful for retrospectively understanding what was actually done.

Nicotinamide adenine dinucleotide (NAD+) is, from a chemical standpoint, not a peptide. It contains no amino acids and no peptide bonds. Its molecular structure is that of a dinucleotide, which is composed of two nucleotide units joined together through their phosphate groups. One of these nucleotides contains an adenine base, while the other contains nicotinamide. Despite its non-peptide identity, NAD+ is frequently included on platforms dedicated to peptide tracking because it shares an identical supply and self-administration workflow. It is commonly supplied as a lyophilized powder in vials, requiring reconstitution with a diluent prior to use, making it a logical candidate for inclusion in tracking and calculation tools.

A primary point of inquiry surrounding NAD+ pertains to its relationship with precursors like nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Both NMN and NR are smaller molecules that the body's metabolic machinery can convert into NAD+. Research protocols that study NMN or NR rely on these endogenous conversion pathways. In contrast, protocols that study direct administration of NAD+ itself, whether via intravenous or subcutaneous routes, bypass these precursor steps entirely by delivering the final coenzyme directly to the body. Documenting which specific molecule is being tracked—the precursor or the final coenzyme—is a foundational step for maintaining a precise and useful log.

NAD+ is a coenzyme involved in cellular energy metabolism and is studied in a wide range of contexts. As with every other entry on this site, mechanistic and clinical specifics are out of scope for a calculator page.

From a biochemical perspective, NAD+ functions as a critical coenzyme in a vast number of cellular processes. Its primary role is as an electron carrier in oxidation-reduction (redox) reactions, which are fundamental to metabolism and cellular energy production. During these reactions, the NAD+ molecule can exist in two forms: its oxidized state (NAD+) and its reduced state (NADH). By cycling between these two forms, it facilitates the transfer of electrons from one molecule to another. Additionally, NAD+ serves as a substrate for several important classes of enzymes, including sirtuins and poly (ADP-ribose) polymerases (PARPs). These enzymes consume NAD+ to carry out their functions, which are subjects of intense study related to cellular maintenance and signaling.

Cadence and dose magnitude vary so much between users that recording the cadence explicitly in each log entry is essential. Without it, retrospective trend analysis is unreliable.

Many NAD+ users alternate between intensive loading periods and lower-frequency maintenance. Recording the transition between phases — the same way it is done for Melanotan-2 — keeps the timeline auditable.

Research protocols for subcutaneous NAD+ administration sometimes describe distinct phases for loading and maintenance. A loading phase might involve a higher frequency of administration, such as daily doses over a period of 5 to 14 days. The objective of such a phase in a research context is to rapidly alter the systemic concentration of the molecule. Following this initial period, the protocol might shift to a maintenance phase, characterized by a reduced frequency, such as a single administration per week. This two-phase structure requires diligent scheduling and tracking to accurately document the shift in dose timing and to monitor observations across both distinct periods of the protocol.

Because NAD+ vials are large, diluent volumes are also typically larger than for peptides. The illustrative example assumes a 100 mg vial reconstituted with 5 mL of bacteriostatic water — concentration of 20 mg per mL. A 50 mg illustrative dose is 2.5 mL or 250 units, which is split across multiple insulin-syringe draws or delivered with a larger syringe.

A unique consideration when planning for subcutaneous NAD+ administration is the large volume of fluid typically required per dose. Based on a common reconstitution scenario, a 100 mg vial reconstituted with 5 mL of diluent results in a concentration of 20 mg/mL. To draw an illustrative dose of 50 mg from this solution, one would need to calculate a total volume of 2.5 mL. This volume, equal to 250 units on a standard U-100 insulin syringe, exceeds the capacity of a single 1 mL (100-unit) syringe. Consequently, users must plan to either use multiple insulin syringes to draw the full volume or utilize a single, larger sterile syringe (e.g., a 3 mL or 5 mL syringe) to accommodate the entire dose in one draw.

Lyophilized NAD+ powder is typically stored refrigerated until reconstitution. The in-use reconstituted vial is kept refrigerated and used within several weeks.

NAD+ is unusual in this list because the cadence is so variable. The dose log itself is the source of truth for what protocol was actually followed; without it, retrospective analysis is essentially guesswork.

Documenting NAD+ administration requires careful attention to the route, as a key differentiator in study protocols is intravenous (IV) versus subcutaneous (SubQ) delivery. IV infusions are typically observed in clinical or research settings, involving large quantities such as 250 mg, 500 mg, or even 1000 mg, infused directly into the bloodstream over several hours. Tracking for this route should include the total dose, infusion duration, and any observed parameters. In contrast, subcutaneous self-administration involves logging much smaller doses (e.g., 50 mg) on a more frequent schedule. A comprehensive tracking log allows for clear delineation between these two methods, ensuring that the recorded data accurately reflects the significant difference in dose magnitude and delivery pharmacokinetics.